entospletinib (GS-9973)

News alerts, weekly reports and conference planners

Company:

Gilead, Kronos Bio

Drug class:

SYK inhibitor

Related drugs:

NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	GS-9973 Sensitive: C2 – Inclusion Criteria GS-9973 Sensitive : C2	GS-9973 Sensitive: C2 – Inclusion Criteria GS-9973 Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	GS-9973 Sensitive: C2 – Inclusion Criteria GS-9973 Sensitive : C2	GS-9973 Sensitive: C2 – Inclusion Criteria GS-9973 Sensitive : C2
KRAS mutation	Childhood B Acute Lymphoblastic Leukemia	KRAS mutation	Childhood B Acute Lymphoblastic Leukemia	GS-9973 Resistant: C3 – Early Trials GS-9973 Resistant : C3	GS-9973 Resistant: C3 – Early Trials GS-9973 Resistant : C3
NRAS mutation	Childhood B Acute Lymphoblastic Leukemia	NRAS mutation	Childhood B Acute Lymphoblastic Leukemia	GS-9973 Resistant: C3 – Early Trials GS-9973 Resistant : C3	GS-9973 Resistant: C3 – Early Trials GS-9973 Resistant : C3
HOXA9 overexpression + MEIS1 overexpression	Acute Myelogenous Leukemia	HOXA9 overexpression + MEIS1 overexpression	Acute Myelogenous Leukemia	GS-9973 Sensitive: C3 – Early Trials GS-9973 Sensitive : C3	GS-9973 Sensitive: C3 – Early Trials GS-9973 Sensitive : C3
MEIS1 overexpression	Acute Myelogenous Leukemia	MEIS1 overexpression	Acute Myelogenous Leukemia	GS-9973 Sensitive: C3 – Early Trials GS-9973 Sensitive : C3	GS-9973 Sensitive: C3 – Early Trials GS-9973 Sensitive : C3
HOXA9 overexpression	Acute Myelogenous Leukemia	HOXA9 overexpression	Acute Myelogenous Leukemia	GS-9973 Sensitive: C3 – Early Trials GS-9973 Sensitive : C3	GS-9973 Sensitive: C3 – Early Trials GS-9973 Sensitive : C3
SF3B1 mutation	Chronic Lymphocytic Leukemia	SF3B1 mutation	Chronic Lymphocytic Leukemia	obinutuzumab + GS-9973 Sensitive: C3 – Early Trials obinutuzumab + GS-9973 Sensitive : C3	obinutuzumab + GS-9973 Sensitive: C3 – Early Trials obinutuzumab + GS-9973 Sensitive : C3
NOTCH1 mutation	Chronic Lymphocytic Leukemia	NOTCH1 mutation	Chronic Lymphocytic Leukemia	obinutuzumab + GS-9973 Sensitive: C3 – Early Trials obinutuzumab + GS-9973 Sensitive : C3	obinutuzumab + GS-9973 Sensitive: C3 – Early Trials obinutuzumab + GS-9973 Sensitive : C3
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	obinutuzumab + GS-9973 Sensitive: C3 – Early Trials obinutuzumab + GS-9973 Sensitive : C3	obinutuzumab + GS-9973 Sensitive: C3 – Early Trials obinutuzumab + GS-9973 Sensitive : C3
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	GS-9973 Sensitive: C3 – Early Trials GS-9973 Sensitive : C3	GS-9973 Sensitive: C3 – Early Trials GS-9973 Sensitive : C3
FLT3‐ITD + NPM1 mutation	Acute Myelogenous Leukemia	FLT3‐ITD + NPM1 mutation	Acute Myelogenous Leukemia	GS-9973 Sensitive: C3 – Early Trials GS-9973 Sensitive : C3	GS-9973 Sensitive: C3 – Early Trials GS-9973 Sensitive : C3
PRDX1 overexpression	Hepatocellular Cancer	PRDX1 overexpression	Hepatocellular Cancer	GS-9973 Sensitive: C3 – Early Trials GS-9973 Sensitive : C3	GS-9973 Sensitive: C3 – Early Trials GS-9973 Sensitive : C3
BTK C481S	Chronic Lymphocytic Leukemia	BTK C481S	Chronic Lymphocytic Leukemia	GS-9973 Sensitive: D – Preclinical GS-9973 Sensitive : D	GS-9973 Sensitive: D – Preclinical GS-9973 Sensitive : D
IL22 overexpression	B Acute Lymphoblastic Leukemia	IL22 overexpression	B Acute Lymphoblastic Leukemia	GS-9973 Sensitive: D – Preclinical GS-9973 Sensitive : D	GS-9973 Sensitive: D – Preclinical GS-9973 Sensitive : D
MLL-AFF1 fusion	Acute Lymphocytic Leukemia	MLL-AFF1 fusion	Acute Lymphocytic Leukemia	selumetinib + GS-9973 Sensitive: D – Preclinical selumetinib + GS-9973 Sensitive : D	selumetinib + GS-9973 Sensitive: D – Preclinical selumetinib + GS-9973 Sensitive : D
MLL-AFF1 fusion + KRAS mutation	Acute Lymphocytic Leukemia	MLL-AFF1 fusion + KRAS mutation	Acute Lymphocytic Leukemia	GS-9973 Sensitive: D – Preclinical GS-9973 Sensitive : D	GS-9973 Sensitive: D – Preclinical GS-9973 Sensitive : D
MLL-AFF1 fusion + NRAS mutation	Acute Lymphocytic Leukemia	MLL-AFF1 fusion + NRAS mutation	Acute Lymphocytic Leukemia	GS-9973 Sensitive: D – Preclinical GS-9973 Sensitive : D	GS-9973 Sensitive: D – Preclinical GS-9973 Sensitive : D
MLL-MLLT3 fusion	Acute Lymphocytic Leukemia	MLL-MLLT3 fusion	Acute Lymphocytic Leukemia	GS-9973 Sensitive: D – Preclinical GS-9973 Sensitive : D	GS-9973 Sensitive: D – Preclinical GS-9973 Sensitive : D
MLL-AFF1 fusion	Acute Lymphocytic Leukemia	MLL-AFF1 fusion	Acute Lymphocytic Leukemia	GS-9973 Sensitive: D – Preclinical GS-9973 Sensitive : D	GS-9973 Sensitive: D – Preclinical GS-9973 Sensitive : D

entospletinib (GS-9973)

Associations
(20)

Associations
(20)

entospletinib (GS-9973)

Associations(20)

Associations(20)

Associations
(20)

Associations
(20)